<DOC>
	<DOCNO>NCT02521441</DOCNO>
	<brief_summary>This randomize , open-label , active-controlled , dose-finding , phase II study evaluate efficacy safety 2 dose F-627 compare Filgrastim woman breast cancer receive myelotoxic chemotherapy . Subjects would randomize one three arm , 10 mg/dose F-627 , 20 mg/dose F-627 Filgrastim , equal ratio .</brief_summary>
	<brief_title>A Phase II , Dose-finding Study F-627 Patients With Breast Cancer Receiving Myelotoxic Chemotherapy .</brief_title>
	<detailed_description>This phase II study conduct 16 clinical center China plan enroll 150 woman breast cancer receive chemotherapy include 4 cycle epirubicin cyclophosphamide , 100 mg/m2 600 mg/m2 , respectively . Subjects would randomize one three arm , 10 mg/dose F-627 , 20 mg/dose F-627 Filgrastim , equal ratio Day 1 study . Patients remain randomized study drug dose regimen follow 3 chemotherapy cycle . The chemotherapy administer chemotherapy cycle 2-4 therapy administer subject Day1 . Chemotherapy administrate intravenous IV ) injection Day 1 21-day cycle repeat every 3 week four cycle unless dose delay necessary . Approximately 48 hour chemotherapy completion cycle ( day 3 cycle ) , patient either receive subcutaneous ( SC ) injection F-627 ( either 10 mg/dose 20 mg/dose ) 5 μg/kg/dose filgrastim use two week stop ANC 5 × 109/L . To track ANC concentration post chemotherapy , subject return study site blood draw either daily ( Cycle 1 ) 3 time per week ( every day ; Cycles 2-4 ) ANC level reach ≥2.0 × 109/L , post-nadir , every 3 day next chemotherapy cycle . All subject return End Study visit approximately 3 week final study drug administration ( Study Day 84 ) follow-up phone call 30 day last study drug .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Willing provide write informed consent compliant study procedure . 2 . 1870 year old ; 3 . Female breast cancer patient resection plan receive 4 cycle chemotherapy ( epirubicin cyclophosphamide , 100 mg/m2 600 mg/m2 , respectively ) . 4 . Score 02 East Cooperative Oncology Group ( ECOG ) . 5 . Absolute neutrophil count ( ANC ) ≥ 2.0 × 109/L , hemoglobin ( Hb ) ≥ 11.0 g/dl , platelet ( PLT ) ≥ 100 × 109/L prior chemotherapy . 6 . Liver kidney function test within normal range . 7 . Left ventricular ejection fraction ( LVEF ) &gt; 50 % . 8 . If female , subject either childbearing potential , childbearing potential . 1 . Patients receive radiotherapy within 4 week prior enrollment . 2 . Patients receive neoadjuvant chemotherapy prior resection breast cancer . 3 . Patients receive bone marrow hemopoietic stem cell transplantation . 4 . Patient malignancy breast cancer . 5 . Patients receive GCSF treatment within 6 week prior enrollment . 6 . Acute congestive heart failure , myocardial disease , myocardial infarction diagnose clinical , electrocardiography , medical procedure . 7 . Any disease possibly cause splenomegaly . 8 . Acute infection , chronic active hepatitis B infection within 1 year ( except subject negative hepatitis B antigen prior enrollment ) history hepatitis C infection . 9 . Pregnancy lactate woman ; female pregnancy potential positive pregnancy test prior study treatment . 10 . Known positive result human immunodeficiency virus ( HIV ) patient acquire immune deficiency syndrome ( AIDS ) . 11 . Patients active tuberculosis ( TB ) , ever history close contact patient TB except negative result tuberculin test ; TB treatment ; suspect TB chest Xray . 12 . Patients sicklecell anemia . 13 . Patients alcohol abuse drug addiction may affect compliance study . 14 . Patients allergy protein extract Escherichia coli , GCSF , drug excipient . 15 . Patients take investigational product within 1 month 5 halflives prior enrollment ( long time period prefer ) base mechanism action . 16 . Patients diseases symptom may suitable enrol study base investigator 's judgment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Myelotoxic Chemotherapy</keyword>
	<keyword>G-CSF</keyword>
</DOC>